2. Search Result
Search Result
Results for "

AXIN

" in MedChemExpress (MCE) Product Catalog:

13

Inhibitors & Agonists

1

Fluorescent Dye

1

Biochemical Assay Reagents

1

Peptides

1

Antibodies

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-108442
    JW67
    1 Publications Verification

    		 Wnt Cancer
    JW67 inhibits the canonical Wnt signaling with an IC50 of 1.17μM . JW67 affects the multiprotein complex consisting of β-catenin/GSK-3β/AXIN/APC/CK1 that rapidly reduces active β-catenin with a subsequent downregulation of Wnt target genes. JW67 also inhibits colorectal cancer cell growth .
    JW67
  • HY-141543
    YW2065

    		β-catenin Cancer
    YW2065 is an Axin-1 stabilizer. Axin-1 is a scaffolding protein that regulates proteasome degradation of β-catenin. YW2065 exhibits anti-colorectal cancer effects via dual activities of wnt/β-catenin signaling inhibition and AMPK activation .
    YW2065
  • HY-122816
    HLY78
    5+ Cited Publications

    		 Wnt β-catenin Apoptosis Cardiovascular Disease Neurological Disease Cancer
    HLY78, a Lycorine (HY-N0288) derivative, is a potent activator of the Wnt/β-catenin signaling pathway. HLY78 targets the DIX domain of Axin and promotes the Axin-LRP6 (lipoprotein receptor-related protein 6) association, thus promoting LRP6 phosphorylation and Wnt signal transduction. HLY78 can be used for subarachnoid hemorrhage (SAH) research .
    HLY78
  • HY-101085
    SKL2001
    Maximum Cited Publications
    45 Publications Verification

    		 Wnt β-catenin Cancer
    SKL2001 is an agonist of the Wnt/β-catenin pathway, with anti-cancer activity. SKL2001 stabilizes intracellular β-catenin via disruption of the Axin/β-catenin interaction .
    SKL2001
  • HY-112799
    DK419

    		Wnt β-catenin Cancer
    DK419 is a potent and orally active Wnt/β-catenin signaling inhibitor, with an IC50 of 0.19 μM. DK419 reduces protein lelvels of Axin2, β-catenin, c-Myc, Cyclin D1 and Survivin and induces production of pAMPK .
    DK419
  • HY-RS01291
    AXIN1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    AXIN1 Human Pre-designed siRNA Set A contains three designed siRNAs for AXIN1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    AXIN1 Human Pre-designed siRNA Set A
    AXIN1 Human Pre-designed siRNA Set A
  • HY-RS01292
    AXIN2 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    AXIN2 Human Pre-designed siRNA Set A contains three designed siRNAs for AXIN2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    AXIN2 Human Pre-designed siRNA Set A
    AXIN2 Human Pre-designed siRNA Set A
  • HY-107528
    FRATtide

    		β-catenin GSK-3 Cancer
    FRATtide is a peptide derived from the GSK-3 binding protein that inhibits the phosphorylation of Axin and β-catenin. FRATtide inhibits GSK-3 binding to Axin .
    FRATtide
  • HY-101085G
    SKL2001 (GMP)

    		Wnt β-catenin Cancer
    SKL2001 (GMP) is SKL2001 (HY-101085) produced by using GMP guidelines. SKL2001 is an agonist of the Wnt/β-catenin pathway, with anti-cancer activity. SKL2001 stabilizes intracellular β-catenin via disruption of the Axin/β-catenin interaction .
    SKL2001 (GMP)
  • HY-108516
    TC-E 5001

    		PARP Cancer
    TC-E 5001 is an inhibitor of Wnt pathway that inhibits tankyrase 1/2 (TNKS1/2) via novel adenosine pocket binding, with Kds of 79 nM and 28 nM, respectively. TC-E 5001 also inhibits Axin2 and STF, with IC50s of 0.709 μM and 0.215 μM, respectively .
    TC-E 5001
  • HY-164467
    CCT070535

    		Wnt Cancer
    CCT070535 blocks TCF-dependent transcription at the TCF level, with GI50 values of 17.6 μM, 11.1 μM, 11.8 μM and 13.4 μM in HT29 (APC mutant), HCT116 (oncogenic β-catenin), SW480 (APC mutant) and SNU475 (Axin mutant) cells, respectively .
    CCT070535
  • HY-123851
    MSC2504877

    M2912

    		 PARP Cancer
    MSC2504877 (M2912) is a potent and orally active tankyrase inhibitor with IC50s of 0.0007, 0.0008, 0.54 µM for TNKS, TNKS2, PARP1, respectively. MSC2504877 increases the expression of AXIN2 and TNKS protein levels and decreases β-catenin levels. MSC2504877 shows anti-tumor activity .
    MSC2504877
  • HY-163767
    Antitumor agent-171

    		β-catenin Inflammation/Immunology Cancer
    Antitumor agent-171 (Compound 35) is an inhibitor for β-catenin/BCL9 interaction with IC50 of 1.61 μM. Antitumor agent-171 exhibits high affinity to β-catenin with Kd of 0.63 μM. Antitumor agent-171 inhibits the gene expression of axin2 with IC50 of 0.84 μM. Antitumor agent-171 inhibits cell viability of HCT116 with IC50 of 4.39 μM. Antitumor agent-171 activates T cells, promotes antigen presentation, and exhibits antitumor efficacy and good pharmacokinetic characteristics in mouse models .
    Antitumor agent-171

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: